Eli Lilly (LLY) Strong Cancer Drug Results
Eli Lilly (LLY) has announced that data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.
The company said that this Phase III clinical trial supported previous studies looking at the use of histology to tailor treatment with ALIMTA for patients with advanced nonsquamous NSCLC. Advanced nonsquamous NSCLC patients on the ALIMTA plus best supportive care arm achieved more than five months increased median overall survival compared to nonsquamous NSCLC patients who received placebo plus best supportive care following initial chemotherapy.
The publication of The Lancet manuscript follows the July 2009 U.S. Food and Drug Administration (FDA) approval of ALIMTA as maintenance therapy for patients with locally advanced or metastatic nonsquamous NSCLC, whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ALIMTA is not indicated for treatment in patients with squamous cell NSCLC. The European Commission also granted a similar approval in July 2009.
Douglas A. McIntyre
Comments
Latest from 247Wallst.com- One-Time Dividends Today Versus Past (GRMN, LTD, MSFT, AXE, INSP)
- World Bank Downplays China Inflation
- Public Offering Floodgates Open Wide (CUZ, DHX, DFS, EPR, FNSR, FPO, GEL, G, GLP, HIG, IRDM, LXRX, NVAX, ORG, SATC, TTMI)
- Today’s Best Market Rumors (3/17/2010)
- Top Analyst Upgrades and Downgrades (ALU, ANN, ATHN, ADSK, BHP, BRCM, CTXS, DO, GHL, MRVL, ERIC)
- Latest from VSInvestor
- Exponential Volume Club (AKNS, BBI, FNM, FUQI, LSI, VIVO, PLCM, SNV, VHC, VLTR)
- Top Day Trader Alerts (ERIC, CIT, FUQI, GGP, PLCM, HOG, GE, ABK)
- Rumors Drive Volume (GGP, SPG, HOG)
- Stock/Option Explosion: The GE Breakout on 52-Week Highs (GE)
- Top Day Trader Alerts (ICGN, SQNM, MPEL, ATHN, BSX, MCHP, GE)
